What is Azitra Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Azitra's operating assets for the quarter that ended in Mar. 2024 was $3.07 Mil. Azitra's operating liabilities for the quarter that ended in Mar. 2024 was $0.94 Mil. Azitra's Total Assets for the quarter that ended in Dec. 2023 was $5.12 Mil. Therefore, Azitra's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.42.
Azitra Scaled Net Operating Assets Historical Data
The historical data trend for Azitra's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azitra Scaled Net Operating Assets Chart
|
Azitra Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
-3.22 |
-3.14 |
0.28 |
|
Azitra Quarterly Data
|
|
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
-4.61 |
0.34 |
0.19 |
0.27 |
0.42 |
Competitive Comparison of Azitra's Scaled Net Operating Assets
For the Biotechnology subindustry, Azitra's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azitra's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Azitra's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Azitra's Scaled Net Operating Assets falls into.
Azitra Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Azitra's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (3.319 | - | 1.316) | / | 7.167 |
| = | 0.28 |
where
Azitra's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (3.067 | - | 0.939) | / | 5.115 |
| = | 0.42 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azitra (Azitra) Business Description
Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Anitra Inc is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
| Fletcher Aaron G.l. |
10 percent owner |
40 GUEST STREET, BOSTON MA 02135 |
| Leslie W. Kreis |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Andrew Mcclary |
director |
21 BUSINESS PARK DRIVE, BRANFORD CT 06405 |
| Aktiengesellschaft Bayer |
10 percent owner |
BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368 |
| Norm Staskey |
officer: Chief Financial Officer |
21 BUSINESS PARK DRIVE, BRANFORD CT 06405 |
| Bios Azitra Co-invest I, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bayer Us Holding Lp |
10 percent owner |
100 BAYER BOULEVARD, WHIPPANY NJ 07981 |
| Bayer Healthcare Llc |
10 percent owner |
|
| Francisco D. Salva |
director, officer: President and CEO |
4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
| Travis Whitfill |
director, officer: Chief Operating Officer |
C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016 |
| Bios Equity Partners Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Qp, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Nt, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Capital Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Azitra (Azitra) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AZTR has been successfully added to your